comparemela.com

Latest Breaking News On - Newly diagnosed advanced ovarian - Page 1 : comparemela.com

Niraparib as Second-line Maintenance Demonstrates Real-world OS Benefit in Recurrent Ovarian Cancer

Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer.

Robertl colemanUs oncology researchFlatiron healthMaintenance therapyRecurrent ovarianNewly diagnosed advanced ovarianAsco annual meeting

AstraZeneca: LYNPARZA (olaparib) and IMFINZI (durvalumab) combination reduced risk of disease progression or death by 37% vs chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated

France generalUnited statesUnited kingdomBrendan mcevoyJessica mcduellSusan galbraithEuropean society of medical oncology congressNational cancer instituteWorld cancer research fund internationalIntj womens healthMerck co incAmerican society of clinical oncologyClinical oncologyAnnual meetingExecutive vice presidentAcute myeloid leukemia

LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® , IMFINZI® , chemotherapy and bevacizumab demonstrated a. | June 3, 2023

France generalUnited kingdomUnited statesSusan galbraithNational cancer instituteEuropean society of medical oncology congressWorld cancer research fund internationalMerck co incAmerican society of clinical oncologyIntj womens healthClinical oncologyAnnual meetingExecutive vice presidentAcute myeloid leukemiaFetal toxicityFirst line maintenance

AstraZeneca: LYNPARZA (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials

Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with

Sao pauloUnited kingdomRhode islandUnited statesIsabelle ray coquardPaul disilvestroJessica mcduellBrendan mcevoyEliav barrSusan galbraithInvestigateurs national des etudes cancers ovariensNational cancer instituteMerck research laboratoriesEuropean network of gynaecological oncological trialEuropean society of medical oncologyResearch association de recherche

Combination of surgery and chemo offers best hope for ovarian cancer

Ovarian cancer is the second most diagnosed gynaecological cancer but the leading cause of death from gynaecological cancer in the developed world,1

United kingdomSri lankaIrish cancer societyWomen health initiativeNational cancer control programmeClinical researchLiving well cancer programmeClinical research fellowLynch syndromeMater hospitalHealth initiativeUnited kingdom collaborative trialOvarian cancer screeningMaintenance therapyRecurrent ovarianNewly diagnosed advanced ovarian

vimarsana © 2020. All Rights Reserved.